Join
Live feed
·
INSIDERFilingvia Quantisnow
Dyne Therapeutics Inc. logo

Chief Medical Officer Kerr Douglas sold $28,715 worth of shares (1,564 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 170,042 units (SEC Form 4) to satisfy withholding obligation

ByQuantisnow·Wall Street's wire, on your screen.
DYN· Dyne Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.